Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis

Accuracy of the enhanced liver fibrosis (ELF) test and combination of ELF and noninvasive tests for the diagnosis of advanced liver fibrosis in patients with nonalcoholic fatty liver disease

(2020) Chika Inadomi et al.   HEPATOLOGY RESEARCH

Hepatic molecular signatures highlight the sexual dimorphism of Non‐Alcoholic SteatoHepatitis (NASH)

(2020) Jimmy Vandel et al.   HEPATOLOGY

Non‐invasive diagnosis of non‐alcoholic steatohepatitis and advanced fibrosis in Japan: A targeted literature review

(2020) Yuichiro Eguchi et al.   HEPATOLOGY RESEARCH

Diagnostic accuracy of FibroScan‐AST score to identify non‐alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non‐alcoholic fatty liver disease: Comparison between M and XL probes

(2020) Satoshi Oeda et al.   HEPATOLOGY RESEARCH

Clinical and anthropometric characteristics of non‐obese non‐alcoholic fatty liver disease subjects in Japan

(2020) Takashi Shida et al.   HEPATOLOGY RESEARCH

Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase‐4 inhibitor on hepatic fibrosis

(2019) Naotaka Shimozato et al.   HEPATOLOGY RESEARCH

Ledipasvir and sofosbuvir for 12 weeks for hepatitis C virus genotype 2 infection: A propensity score matched analysis

(2019) Eiichi Ogawa et al.   HEPATOLOGY RESEARCH

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

(2019) Zobair M Younossi et al.   LANCET

The gut–liver axis and the intersection with the microbiome

(2018) Anupriya Tripathi et al.   Nature Reviews Gastroenterology & Hepatology

Combining probiotics and an angiotensin‐II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non‐alcoholic steatohepatitis

(2018) Yasuhiko Sawada et al.   HEPATOLOGY RESEARCH

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis

(2017) Parambir S. Dulai et al.   HEPATOLOGY

Toll-Like Receptor 4 Modulates Small Intestine Neuromuscular Function through Nitrergic and Purinergic Pathways

(2017) Valentina Caputi et al.   Frontiers in Pharmacology

Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats

(2016) María Úbeda et al.   JOURNAL OF HEPATOLOGY

Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease

(2016) Serena Pelusi et al.   PLoS One

The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and Bacterial Translocation in Cholestatic Rats

(2015) Len Verbeke et al.   AMERICAN JOURNAL OF PATHOLOGY

Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis

(2015) Tadashi Namisaki et al.   JOURNAL OF GASTROENTEROLOGY

Current efforts and trends in the treatment of NASH

(2015) Vlad Ratziu et al.   JOURNAL OF HEPATOLOGY

Lipopolysaccharide Regulation of Intestinal Tight Junction Permeability Is Mediated by TLR4 Signal Transduction Pathway Activation of FAK and MyD88

(2015) Shuhong Guo et al.   JOURNAL OF IMMUNOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Role of Gut Barrier Function in the Pathogenesis of Nonalcoholic Fatty Liver Disease

(2015) Xin Dai et al.   Gastroenterology Research and Practice

Sex differences in metabolic homeostasis, diabetes, and obesity

(2015) Franck Mauvais-Jarvis   Biology of Sex Differences

Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model

(2014) AKITOSHI DOUHARA et al.   Molecular Medicine Reports

Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis

(2013) Yusaku Shirai et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Telmisartan, an AT1 receptor blocker and a PPAR gamma activator, alleviates liver fibrosis induced experimentally by Schistosoma mansoni infection

(2013) Yasmeen M Attia et al.   Parasites & Vectors

Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis

(2012) Ryuichi Noguchi et al.   HEPATOLOGY RESEARCH

Prevalence, gender, ethnic variations, and prognosis of NASH

(2010) Etsuko Hashimoto et al.   JOURNAL OF GASTROENTEROLOGY

Farnesoid X Receptor Critically Determines the Fibrotic Response in Mice but Is Expressed to a Low Extent in Human Hepatic Stellate Cells and Periductal Myofibroblasts

(2009) Peter Fickert et al.   AMERICAN JOURNAL OF PATHOLOGY